EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apoptosis Inhibitor of Macrophage and Acute Inflammation in IgA Nephropathy

Rina Kato, Hitoshi Suzuki iD, Ryosuke Aoki iD, Ayako Koizumi iD, Yusuke Fukao iD, Maiko Nakayama iD, Yoshihito Nihei iD, Toshiki Kano iD, Yuko Makita, Masahiro Muto, Keisuke Yasuda iD, Satoko Arai iD und 2 weitere

Kidney360 · 2026-08 · 7 (8) · 1842-1853

DOI: 10.34067/kid.0000001202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney360, online erschienen am 22.05.2026. Verfasst von Rina Kato und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED-LEAP, the Japan Agency for Medical Research Development, AMED-LEAP, the Japan Agency for Medical Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Serum IgM-free apoptosis inhibitor of macrophage reflects disease activity in human IgA nephropathy. Glomerular apoptosis inhibitor of macrophage deposition was colocalized with mesangial IgA and reflected the acute glomerular injuries by complement activation. Multivariate Cox regression analysis revealed serum IgM-free apoptosis inhibitor of macrophage as an independent predictor of hematuria remission in patients.

Background

IgA nephropathy is characterized by mesangial deposits of IgA1-containing immune complex with complement 3. Our previous study demonstrated that apoptosis inhibitor of macrophage (AIM) plays a critical role in in situ IgA-containing immune complex formation and subsequent complement activation in murine IgA nephropathy. We further evaluated the clinicopathologic role of AIM in human IgA nephropathy.

Methods

We enrolled 77 patients with IgA nephropathy, five patients with thin basement membrane disease as disease controls, and 40 age-matched healthy individuals as healthy controls. We analyzed the association between serum IgM-free AIM (sAIM)/glomerular AIM (gAIM) deposition area and clinicopathologic features. Results sAIM level was higher in patients with IgA nephropathy at diagnosis than in disease and healthy controls (1.02±0.49 versus 0.56±0.19 versus 0.57±0.20 µ g/ml), significantly decreased to 0.67±0.44 µ g/ml after tonsillectomy and steroid pulse therapy, and was associated with serum IgA ( r 2 =0.23) and IgA–IgG immune complex levels ( r 2 =0.12). gAIM was colocalized with mesangial IgA and high intensity of gAIM was associated with the degree of hematuria (30–49 versus 10–19 per high-power field) and acute lesions, including those with Oxford classification scores of endocapillary hypercellularity (E1 3% versus E0 2%) and crescent formation (C1 3% versus C0 2%). Furthermore, gAIM deposition was positively correlated with glomerular complement 3 deposition ( r 2 =0.54). Multivariate Cox regression analysis revealed sAIM as an independent predictor of hematuria remission (hazard ratio, 1.86; 95% confidence interval, 1.03 to 3.15). According to Kaplan–Meier analysis, patients with larger reduction of sAIM (≥0.45 µ g/ml) after tonsillectomy and steroid pulse therapy showed a significantly improved hematuria (6 versus 9 months).

Conclusions

We suggest that IgA nephropathy patients with high sAIM levels have high disease activity and patients with high intensity of gAIM deposition have acute glomerular injuries leading to hematuria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAHumansMaleFemaleAdultImmunoglobulin AHematuriaMiddle AgedCase-Control StudiesComplement C3Complement ActivationInflammationGlomerular MesangiumAntigen-Antibody ComplexApoptosis Regulatory ProteinsReceptors, Scavenger

Stichwörter der Autor:innen

IgA nephropathycomplement

Substanzen

Immunoglobulin ACD5L protein, humanComplement C3Antigen-Antibody ComplexApoptosis Regulatory ProteinsReceptors, Scavenger

Autor:innen und Institutionen

  • Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • The Institute for AIM Medicine, Tokyo, Japan.
  • Laboratory of Food Chemistry, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Hitoshi Suzuki, Ryosuke Aoki, Ayako Koizumi, Yusuke Fukao, Maiko Nakayama, Yoshihito Nihei, Toshiki Kano, Keisuke Yasuda, Satoko Arai, Toru Miyazaki, Yusuke Suzuki

Förderung

  • AMED-LEAP, the Japan Agency for Medical Research Development
  • AMED-LEAP
  • the Japan Agency for Medical Research Development

Zitieren

APA

Kato, R., Suzuki, H., Aoki, R., Koizumi, A., Fukao, Y., Nakayama, M., Nihei, Y., Kano, T., Makita, Y., Muto, M., Yasuda, K., Arai, S., Miyazaki, T., & Suzuki, Y. (2026). Apoptosis Inhibitor of Macrophage and Acute Inflammation in IgA Nephropathy. Kidney360, 7(8), 1842-1853. https://doi.org/10.34067/kid.0000001202

Vancouver

Kato R, Suzuki H, Aoki R, Koizumi A, Fukao Y, Nakayama M, et al. Apoptosis Inhibitor of Macrophage and Acute Inflammation in IgA Nephropathy. Kidney360. 2026;7(8):1842-1853. doi:10.34067/kid.0000001202

BibTeX
@article{Kato2026,
  author = {Kato, Rina and Suzuki, Hitoshi and Aoki, Ryosuke and Koizumi, Ayako and Fukao, Yusuke and Nakayama, Maiko and Nihei, Yoshihito and Kano, Toshiki and Makita, Yuko and Muto, Masahiro and Yasuda, Keisuke and Arai, Satoko and Miyazaki, Toru and Suzuki, Yusuke},
  title = {Apoptosis Inhibitor of Macrophage and Acute Inflammation in IgA Nephropathy},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {8},
  pages = {1842--1853},
  doi = {10.34067/kid.0000001202}
}
Kostenlos starten →